[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-419257-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-419257-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","osimertinib-retreatment-for-patients-with-advanced-egfr-mutated-non-small-cell-lung-cancer","Osimertinib retreatment for patients with advanced EGFR-mutated non-small cell lung cancer","","Resistance to osimertinib, a third-generation EGFR tyrosine kinase inhibitor, remains a key challenge in EGFR-mutated non-small cell lung cancer (NSCLC). While retreatment with earlier EGFR TKIs has been studied, evidence for osimertinib rechallenge is limited. A single-institution retrospective analysis evaluated patients rechallenged with osimertinib after progression on prior osimertinib and interim systemic therapy. Seventeen patients met criteria; 18% achieved partial response and 35% stable disease, for a 53% disease control rate. Median retreatment duration was 4.3 months and overall survival after initiation was 8.9 months.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/osimertinib-retreatment-for-patients-with-advanced-egfr-mutated-non-small-cell-lung-cancer/419257/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/osimertinib-retreatment-for-patients-with-advanced-egfr-mutated-non-small-cell-lung-cancer/419257.png","ImageObject",300,407,{"name":42,"@type":43},"Terk","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-28",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Who were included in the osimertinib rechallenge analysis?","Question",{"text":63,"@type":64},"Patients with EGFR-mutated NSCLC who progressed on prior osimertinib and then received interim systemic therapy, including chemotherapy, were included. Seventeen patients met criteria and all had adenocarcinoma histology with exon 19 deletions or L858R mutations.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What outcomes were observed after osimertinib retreatment?",{"text":68,"@type":64},"Osimertinib retreatment produced a partial response in 18% (3/17) and stable disease in 35% (6/17). The resulting disease control rate was 53% (9/17), with median retreatment duration of 4.3 months.",{"name":70,"@type":61,"acceptedAnswer":71},"What factors were evaluated regarding benefit from retreatment?",{"text":72,"@type":64},"The study assessed intracranial involvement and whether the duration of initial osimertinib therapy predicted retreatment benefit. Intracranial stability without additional radiation was reported in some patients, while the initial osimertinib duration did not strongly predict benefit.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},419257,1790762983,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":4},1099525198933,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Author Manuscript Author Manuscript Author Manuscript Author Manuscript  \n\n| | HHS Public Access\u003Cbr>Author manuscript\u003Cbr>Cancer Treat Res Commun. Author manuscript; available in PMC 2026 January 02. |\n| --- | --- |\n\nPublished in final edited form as:  \nCancer Treat Res Commun. 2025 ; 45: 101026. doi:10.1016/j.ctarc.2025.101026 .  \nOsimertinib retreatment for patients with advanced EGFRmutated non-small cell lung cancer  \nKevin M. Levinea,b, Natalie F. Uya,b, Ted A. Gooleyb, Jenna Voutsinasb, Micah Trattb, Keith D. Eatona,b, Rafael Santana-Davilaa,b, Alice H. Bergerb, Christina S. Baika,b,*  \na University of Washington, Seattle, WA, USA  \nb Fred Hutchinson Cancer Center, Seattle, WA, USA  \nAbstract  \nResistance to osimertinib, a third-generation EGFR tyrosine kinase inhibitor, remains a key challenge in the treatment of EGFR-mutated non-small cell lung cancer (NSCLC) . Although retreatment with earlier-generation EGFR tyrosine kinase inhibitors has been studied, data onosimertinib rechallenge are limited. We conducted a single institution retrospective analysis of patients with EGFR-mutated NSCLC who were rechallenged with osimertinib following progression on prior osimertinib and interim systemic therapy, including chemotherapy. Seventeen patients met inclusion criteria, all with adenocarcinoma histology and either EGFR exon 19 deletions or L858R mutations. Median interval between osimertinib treatments was 10.5 months. Osimertinib retreatment resulted in a partial response in 18 %(3/17) and stable disease in 35 % of patients (6/17), for a disease control rate of 53 %(9/17) . Median retreatment duration was 4.3 months, and median overall survival following retreatment initiation was 8.9 months.  \nAmong patients with central nervous system involvement, several experienced intracranial stability without additional radiation. Duration of initial osimertinib therapy did not strongly predict retreatment benefit. These findings suggest that osimertinib rechallenge may provide clinically meaningful disease control in a subset of patients, especially given its tolerability and oral formulation. Further research is needed to identify biomarkers of sensitivity and to optimize patient selection for osimertinib retreatment following interval chemotherapy.  \nKeywords  \nOsimertinib; Retreatment; Rechallenge; Targeted therapy; Lung cancer  \nThis is an open access article under the CC BY license ([http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/)).  \n*[Corresponding author. cbaik2@uw.edu](Corresponding author. cbaik2@uw.edu) (C. S. Baik) .  \nEthics statement  \nThis study was approved by the University of Washington Institutional Review Board (Protocol Number 00015006) and all members of the study team were trained in Human Subjects Research. Due to the retrospective nature of the study, the IRB approved a waiver for informed consent to share de-identified data.  \nCRediT authorship contribution statement  \nKevin M. Levine: Writing – review & editing, Writing – original draft, Formal analysis, Data curation. Natalie F. Uy: Writing  \n– review & editing, Writing – original draft, Formal analysis, Data curation. Ted A. Gooley: Writing – review & editing, Formal analysis. Jenna Voutsinas: Writing – review & editing, Formal analysis. Micah Tratt: Writing – review & editing, Data curation. Keith D. Eaton: Writing – review & editing, Data curation. Rafael Santana-Davila: Writing – review & editing, Data curation. Alice H. Berger: Writing – review & editing, Supervision. Christina S. Baik: Writing – review & editing, Supervision, Conceptualization.  \nAuthor Manuscript Author Manuscript Author Manuscript Author Manuscript  \nLevine et al. Page 2  \nIntroduction  \nOsimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) approved as front-line therapy for patients with advanced non-small cell lung cancer (NSCLC) whose tumors harbor activating EGFR mutations [1] . Osimer","cbCair5gDddLDKVC","https://ap.wps.com/l/cbCair5gDddLDKVC","pdf",495784,11,"English","# Abstract\n## Introduction\n## Keywords","[{\"question\":\"Who were included in the osimertinib rechallenge analysis?\",\"answer\":\"Patients with EGFR-mutated NSCLC who progressed on prior osimertinib and then received interim systemic therapy, including chemotherapy, were included. Seventeen patients met criteria and all had adenocarcinoma histology with exon 19 deletions or L858R mutations.\"},{\"question\":\"What outcomes were observed after osimertinib retreatment?\",\"answer\":\"Osimertinib retreatment produced a partial response in 18% (3/17) and stable disease in 35% (6/17). The resulting disease control rate was 53% (9/17), with median retreatment duration of 4.3 months.\"},{\"question\":\"What factors were evaluated regarding benefit from retreatment?\",\"answer\":\"The study assessed intracranial involvement and whether the duration of initial osimertinib therapy predicted retreatment benefit. Intracranial stability without additional radiation was reported in some patients, while the initial osimertinib duration did not strongly predict benefit.\"}]","Osimertinib retreatment for patients with advanced EGFR-mutated non-small cell lung cancer | PDF",1790616335,28]